Keyword: Christi Shaw

Back in May, new Gilead CEO Daniel O’Day said he’d be looking for a CEO for Gilead’s Kite unit. And he’s found his pick.

After a little more than two years in her position, Lilly Bio-Medicines head Christi Shaw is stepping down at the end of August.

Two of Eli Lilly's key growth drivers came up short in the first quarter, and execs faced a grilling on what they plan to do about it.

Despite its CGRP drug Emgality's third-to-market status, Lilly has big plans for a growing stable of migraine and pain drugs, an exec said.

Lilly analysts worry growth could suffer if it doesn't win a nod for both baricitinib doses—and an FDA panel shot down one of them Monday.

With more than 2,000 early retirements settled, Eli Lilly says it's "on track" to hit its goal of cutting 3,500 jobs by year's end.

Lilly CEO David Ricks has overhauled his team twice since he took over in January, and this time he's focusing on manufacturing, tech and R&D.

At Eli Lilly, the new year comes with a shakeup in its commercial organization, with vet Enrique Conterno taking the reins in the U.S. and ex-Novartis exec Christi Shaw joining as head of Bio-Medicines.